Nanjing Leads Biolabs Co., Ltd.
π¨π³China
- Country
- π¨π³China
- Ownership
- Holding, Subsidiary
- Established
- 2012-11-27
- Employees
- 1
- Market Cap
- -
- Website
- http://leadsbiolabs.com
Leads Biolabs' LBL-024 Receives Breakthrough Therapy Designation in China for EP-NEC
β’ The CDE of China's NMPA granted Breakthrough Therapy Designation to LBL-024 for advanced extrapulmonary neuroendocrine carcinoma (EP-NEC) post-chemotherapy.
β’ LBL-024, a bispecific antibody targeting PD-L1 and 4-1BB, showed remarkable efficacy and safety in EP-NEC patients who had failed second-line chemotherapy.
β’ Clinical data indicates LBL-024 monotherapy more than doubled both the Objective Response Rate (ORR) and Overall Survival (OS) compared to existing treatments.
β’ Leads Biolabs plans to aggressively pursue global clinical development of LBL-024 to provide more effective treatment options for EP-NEC patients.
Β© Copyright 2025. All Rights Reserved by MedPath